Zelira Therapeutics (ZLDAF, $0.38) was a top loser over the last three months, falling -1 to $0.38 per share. A.I.dvisor analyzed 856 stocks in the Biotechnology Industry for the 3-month period ending December 31, 2024, and found that of them (3) exhibited an Uptrend while of them (6) demonstrated a Downtrend.